TORONTO, ON / ACCESSWIRE / July 26, 2016 / Minnova Corp. (TSXV: MCI) (OTC Pink: AGRDF) (“Minnova” or “the Company”) is pleased to provide a corporate update on its ongoing 2016 technical programs which include detailed core re-logging at the PL Deposit and regional geologic structural lineament analysis targeting gold mineralization.

A detailed review of drill core from the initial 2011 Minnova drill program has identified that several holes where stopped short of the lower vein structures. Initial drilling in 2011 was focused on development of shallow open pits. Several shallow drill holes targeting near surface vein mineralization on the upper Sherridon Vein were terminated in the immediate footwall to that vein intercept. The Sherridon Vein overlies 3 other mineralized veins, namely; the Upper Vein, Main Vein and Lower Vein, which collectively make up the current PL deposit resource. By extending these drill holes between 50 and 75 meters we can effectively and efficiently in-fill drill a portion of the existing resource base on the lower veins. This work will be incorporated into the stage 2 drill program planned for the fall of 2016 to expand and upgrade the existing PL Deposit resource.

A detailed structural analysis of the PL Property and regional geology using lineament analysis and analogue modeling was initiated in May 2016 to identify high priority structural targets that could host gold mineralization. Maps of all lineaments on the property and regionally (Tertiary (smallest), Secondary (medium), Primary (regional scale) and Circular (most often reflect intrusive bodies underneath)) have been compiled and analysis is ongoing. Initial spatial correlation between the Primary lineaments and existing geophysical (VTEM) survey features is positive with many Primary lineament intersections being coincident with areas of known gold mineralization. This work continues with physical modeling (analogue clay modeling of elastic and plastic/rapture fields) to understand the pattern of dilatational structures on the mine property and regionally. The results of this work will be followed-up later in the summer with a program of detailed structural geology fieldwork, ground-truthing coincident structural and geophysical targets and gold prospecting.

Gorden Glenn, CEO commented “as many of our stakeholders know the Flin Flon-Snow Lake Greenstone Belt has a prolific history of primarily base metal production (Copper and Zinc). Primary gold production and gold exploration has been rather limited due to the dominance of one major, base metal focused, mining company since the camps first major discovery, the Flin Flon deposit in 1914. While there is also significant gold mineralization associated with the many of the base metal deposits in the camp sustained gold focused exploration has been relatively minor compared to other major mining camps in Canada. We hope to capitalize on this by taking a first principles approach to property-wide and regional gold exploration. The first step in this process is the detailed structural lineament analysis that we initiated, the first such technical analysis of the minor and major structural features in the Sherridon-Puffy Lake area that we are aware of. Results to date are very encouraging and support our view that the regions gold exploration potential has not been fully tested away from the known PL and Nokomis gold deposits. Detailed structural lineament analysis plus ongoing in-fill drill programs planned for the fall are all aimed at expanding the existing PL deposit and discovery of new deposits that can be rapidly advanced to production utilizing our existing PL Mine infrastructure.”

Qualified Person

Mr. Brian Robertson, B. Sc., P. Eng.., a Director of the Company and a “Qualified Person” under National Instrument 43-101, has reviewed and approved the scientific and technical information in this press release.

For more information please contact:

Minnova Corp.

Gorden Glenn

President & Chief Executive Officer

For further information, please contact Investor Relations at 647-985-2785 or info@minnovacorp.ca.

Visit our website at www.minnovacorp.ca.

Forward Looking Statements

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, information regarding the Company including management’s assessment of future plans and operations, that may involve risks associated with mining exploration and development, volatility of prices, currency fluctuations, imprecision of resource estimates, environmental and permitting risks, access to labour and services, competition from other companies and ability to access sufficient capital. As a consequence, actual results may differ materially from those anticipated in the forward looking statements. A feasibility study has not been completed and there is no certainty the disclosed targets will be achieved nor that the proposed operations will be economically viable. Although Minnova has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. Minnova does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Minnova Corp.

ReleaseID: 442855

NEW YORK, NY / ACCESSWIRE / July 26, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against of CPI Card Group, Inc. (“CPI” or the “Company”) (NASDAQ: PMTS) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired CPI common stock in connection with CPI’s October 8, 2015 initial public offering (“IPO”), including purchasers of the common stock in the aftermarket.

CPI is a prominent provider of electronic payment cards and associated services, offering a single source for credit, debit and prepaid debit cards, including “EMV” (Europay, MasterCard and Visa) chip, personalization, instant issuance, fulfillment and mobile payment services.

The complaint alleges that at the time of the IPO, CPI had shipped over 100 million cards more than shipped in the second quarter and first part of the third quarter of 2015. Unbeknownst to investors at the time, this shipment created a massive backlog with those customers, which significantly reduced the demand for additional card shipments in the fourth quarter of 2015 and fiscal 2016. The unfavorable dealings and uncertainties linked with CPI’s largest customers’ inventory levels were likely to impact on CPI’s profitability and, therefore, should have been disclosed in the Registration Statement.

CPI sold 17.25 million shares of common stock during its IPO at $10 per share, raising $172.5 million. At the time the complaint was filed, CPI common stock was trading at about $4.70 per share – 53% less than the IPO price.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/#!cpi/edd1e or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in CPI and purchased the common stock in or pursuant to CPI’s October 8, 2015 IPO, including purchasers of the common stock in the aftermarket (the “Class”) you have until August 15, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442283

NEW YORK, NY / ACCESSWIRE / July 26, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ-GM: IMMU). The class action has been filed in the United States District Court, District of New Jersey, on behalf of a class consisting of all persons or entities who purchased Immunomedics common stock between April 20, 2016 and June 2, 2016 inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

Immunomedics is a clinical-stage biopharmaceutical company that researches, develops, manufactures and sells monoclonals and ELISA kits, for use in cancer and autoimmune diagnosis, detection and therapy.

Immunomedics is known for its antibody-drug conjugate sacituzumab govitecan IMMU-132 (“IMMU-132”), currently in Phase II trials for treatment of patients with metastatic triple-negative breast cancer and small-cell and non-small-cell lung cancers.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the abstract for IMMU-132 that Immunomedics submitted to the American Society of Clinical Oncology (“ASCO”) for presentation at the 2016 ASCO Annual Meeting contained outdated results from a mid-stage study; (2) Immunomedics had misrepresented this information to ASCO as if its abstract IMMU-132 only listed updated and previously undisclosed data; (3) the misrepresentation was a violation of ASCO policy and made Immunomedics’ IMMU-132 presentation subject to removal from the 2016 ASCO Annual Meeting schedule; and (4) consequentially, Immunomedics’ public statements were materially false and misleading at all relevant times.

On April 19, 2016, Immunomedics said it would update its results for IMMU-132 treatment for ASCO’s Annual Meeting scheduled in June 2016.

On June 2, 2016, after the market closed, media outlets reported that the American Society of Clinical Oncology (“ASCO”) had removed a scheduled presentation by Immunomedics regarding the Company’s IMMU-132 breast cancer drug from ASCO’s annual meeting. ASCO stated that Immunomedics had misrepresented that the Company’s abstract for IMMU-132 contained updated and previously undisclosed results from a mid-stage study, when in fact the IMMU-132 data that Immunomedics submitted were old and previously seen.

Following this news, Immunomedics stock dropped $0.78, or 14.72%, to close at $4.52 on June 3, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action please visit the firm’s site: http://www.bgandg.com/#!immu/sypgi or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Immunomedics you have until August 8, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441622

NEW YORK, NY / ACCESSWIRE / July 26, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against Oracle Corporation (“Oracle” or “the Company”) (NYSE: ORCL). The class action has been filed in the United States District Court, Northern District of California, on behalf of a class consisting of all persons or entities who purchased Oracle securities during the period between September 16, 2015 and June 1, 2016 inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Oracle used improper accounting practices to inflate the Company’s cloud computing revenues by millions of dollars; (ii) in violation of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) and the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), Oracle had terminated a Senior Finance Manager for raising the Company’s improper accounting practices to the attention of her supervisors; and (iii) as a result of the foregoing, Oracle’s public statements were materially false and misleading at all relevant times.

On June 1, 2016, after the market closed, media outlets reported that a former Senior Finance Manager at Oracle, Svetlana Blackburn (“Blackburn”), had sued the Company for terminating her for complaining about improper accounting practices in Oracle’s cloud services business. In a complaint filed in U.S. District Court for the Northern District of California, Blackburn accused Oracle’s upper management of trying to push her to “fit square data into round holes” to make Oracle Cloud Services’ results look better. Blackburn’s lawsuit accused Oracle of violating the anti-retaliation provisions of the Sarbanes-Oxley Act and the Dodd-Frank Act and alleged that Blackburn was terminated on October 15, 2015, just one month after the alleged wrongdoing began, and two months after she received a positive performance review.

On this news, Oracle stock fell $1.60, or 3.97%, to close at $38.66 on June 2, 2016.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action please visit the firm’s site: http://www.bgandg.com/#!orcl/ip9g0 or contact Peretz Bronstein, Esq. or his Investor Relations Coordinator, Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Oracle you have until August 1,
2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 442267

NEW YORK, NY / ACCESSWIRE / July 26, 2016 / Bronstein, Gewirtz & Grossman, LLC, notifies investors
of class action against of Neovasc, Inc. (“Neovasc” or “the Company”) (NASDAQ: NVCN). The class action has been filed on behalf of a class consisting of all persons or entities who purchased Neovasc securities during the period between January 26, 2015, and May 19, 2016, inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

Neovasc is a specialty medical company that develops cardiovascular products. Neovasc’s primary product is the Tiara, a transcatheter mitral valve device used to treat mitral valve disease. This device can be implanted through minimally invasive surgery to patients with mitral regurgitation resulting from mitral heart valve disease.

The Complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about Neovasc’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (1) Neovasc’s Tiara device was advanced through dishonest business practices, including the embezzlement of trade secrets from another company; (2) that there was a related and legitimate lawsuit against Neovasc regarding
the misappropriation of trades secrets; and (3) consequentially, Defendants’ statements about Neovasc’s business, operations, and prospects were materially false and misleading at relevant times. Following this information entering the market, investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action, visit the firm’s website: http://www.bgandg.com/#!nvcn/m3197. To discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Neovasc you have until August 5, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441335

NEW YORK, NY / ACCESSWIRE / July 26, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court, District of Massachusetts on behalf of those who purchased shares of Chiasma, Inc. (“Chiasma” or the “Company”) (NASDAQ: CHMA) between July 15, 2015 and April 17, 2016 inclusive (the “Class Period”).

Chiasma is a biopharmaceutical company focused on developing and commercializing orphan medications to better meet the needs of patients and healthcare professionals.

Chiasma’s leading product is oral octreotide, Mycapssa, used to treat acromegaly, a condition resulting from excess growth
hormone. As of June 2015, Chiasma had finished its multinational Phase 3 clinical trial of Mycapssa and submitted a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for approval to market and sell Mycapssa. On or about July 15, 2016, Chiasma completed its IPO, issuing 6.4 million shares and raising approximately $102 million of net proceeds.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Chiasma’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Chiasma’s Phase 3 clinical trial for Mycapssa was not adequate to show effectiveness and for FDA approval; (2) Chiasma’s management of its suppliers was not adequate to avoid mistakes, thus delaying FDA approval; and (3) consequentially, Chiasma’s public statements were materially false and misleading at all relevant times.

On April 18, 2016, premarket, Chiasma announced that the FDA had issued a Complete Response Letter for Mycapssa’s NDA, explaining that the FDA did not see ample proof of efficacy to warrant approval and advising the Company to conduct another clinical trial to address this deficiency. The FDA also listed its apprehensions about certain aspects of the Company’s single-arm, open-label Phase 3 clinical trial and strongly recommended a randomized, double-blind and controlled trial that enrolls patients from the United States and for a long enough duration to ensure that control of disease activity is stable at the time point selected for the primary efficacy assessment. The FDA instructed that certain deficiencies that were found at a recent site inspection would also need to be resolved before approval.

Following this news, Chiasma stock dropped $6.42 per share, or 63.13%, to close at $3.75 on April 18, 2016.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint or join the action, please visit the firm’s site: http://www.bgandg.com/#!chma/ts6n9. To discuss this action, or for any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Chiasma you have until August 8, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 441188

NEW YORK, NY / ACCESSWIRE / July 26, 2016 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on One Horizon Group, Inc. (NASDAQ: OHGI).

The report is available here: OHGI July 2016 Update Note.

“It’s clear that the focus of management has been on the Aishuo business. As we noted in our October 2015 update, the company has been focused on growing the subscriber base of this business. Revenues in this segment have grown quickly from a small base, rising from $30,000 in 4Q15 to $60,000 in 1Q16, while subscriber downloads surpassed 37mn as of July 19, 2016, well ahead of the target set out by management last year,” stated Ajay Tandon, CEO of SeeThruEquity.

Additional highlights from the update note are as follows:

Investment Highlights

New “Roam Like Home” offering expands carrier possibilities

We were encouraged to see OHGI launch a compelling new service for emerging market carriers. In April, the company announced an attractive feature for emerging market carriers called, “Roam Like Home,” which appears to have had some initial success, as evidenced by OHGI announcing operators that have signed up for the service, including Smart Communications, the largest wireless service provider in the Philippines with over 55mn prepaid subscribers, that have already begun deploying the service since June. Roam Like Home offers subscribers the ability to take advantage of low coast roaming when travelling outside of their home market. It also has distinct advantages for carriers in their battle against competition from over-the-top services such as Skype, by enabling carriers to continue to profit from their prepaid subscribers even when they are roaming. According to the announcement by the company, Roam Like Home makes offering roaming service 5x – 17x more cost effective for carriers by using OHGI’s patented low data usage SmartPacket™ mobile VoIP smartphone app with the low inter-operator data roaming rates. The new service should create incremental revenue for OHGI’s service provider clients, who were previously losing revenues, as high data roaming fees were forcing prepaid subscribers to use WIFI-based OTT services when roaming.

Aishuo surpasses 37mn downloads ahead of expectations

OHGI has been focused on the launch and rollout of Aishuo, its retail VoIP service in China. We have been impressed by the pace at which the company has added downloads, and note that on July 19, 2016, the company announced that Aishuo had surpassed 37mn downloads. The figure is well ahead of our thinking, and also the company’s stated goal of reaching 15mn subscriber downloads by 1Q17. With 37mn in July, it now appears that management has more than doubled its initial goal. Having accomplished Phase 1 of is plan, we are now looking for OHGI to provide additional detail about its subscribers, including usage metrics and a clarification between subscriber downloads and active subscribers. We are also eager to learn more about the how management sees the scope and timing of potential monetization plans including sales of the recently launched Aishuo SIM card for holiday makers. Along these lines, OHGI has begun disclosing Aishuo revenues, which grew by 100% sequentially in 1Q16, grown rapidly albeit from a small base, reaching $60,000 in the quarter.

Please review important disclosures on our website at www.seethruequity.com.

About One Horizon Group, Inc.

One Horizon Group Inc.’s business is to optimize communications over the Internet through its wholly owned subsidiary, Horizon Globex GmbH, which develops and markets one of the world’s most bandwidth-efficient mobile voice over Internet Protocol (VoIP) platforms for smartphones, and also offers a range of other optimized data applications including messaging and mobile advertising. Horizon Globex GmbH is an ISO 9001 and ISO 20000-1 certified company. The Company has operations in Switzerland, the United Kingdom, China, India, Singapore, Hong Kong and Ireland.

For more information on the Company, its products and services, please visit www.onehorizongroup.com.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 442854